Scientific research and evidence-based medicine have consistently demonstrated that phosphatidylserine is the most effective nutrient for reducing the risk of developing or progressing with cognitive dysfunction in elderly individuals or those with dementia. As a leading Phosphatidylserine manufacturer, Frau Pharma supports this evidence through clinically tested formulations.
More than 50 studies have been conducted on PS, including 29 randomized, double-blind, placebo-controlled trials—hallmarks of evidence-based medicine. In these trials, over 1,700 subjects were treated for a total of 170,000 treatment days, with an average duration of 72 days.
Two double-blind clinical studies in the U.S. were conducted as multicenter trials coordinated by Dr. Crook and his collaborators. These studies assessed five different parameters measuring the effects of PS on age-related mental decline. In the older subgroup, researchers estimated that PS supplementation effectively “rolled back the clock” by approximately 12 years.
(Effects of Phosphatidylserine in Age-Associated Memory Impairment and Alzheimer’s Disease | SpringerLink)
Another double-blind crossover study conducted at the University of Mississippi by Starks and colleagues demonstrated that PS supplementation effectively reduces exercise-induced stress.
(The effects of phosphatidylserine on endocrine response to moderate intensity exercise – PubMed)
The clinical results from U.S. and European studies are further supported by an extensive body of preclinical research, highlighting both the mechanism of action and the safety of PS (Phosphatidylserine), reinforcing its place in evidence-based medicine. This scientific foundation strengthens the role of Frau Pharma as a trusted Phosphatidylserine manufacturer globally.
